Patrick Texereau

Mont-sur-meurthe, 40000, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study.

Journal: Cancers
Published: February 19, 2023

Loss of SMARCB1 expression in colon carcinoma.

Loss of SMARCB1 expression in colon carcinoma.

Journal: Cancer biomarkers : section A of Disease markers
Published: February 22, 2020

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 23, 2020

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.

Journal: Expert review of pharmacoeconomics & outcomes research
Published: February 12, 2019

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Journal: The New England journal of medicine
Published: December 22, 2018

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Journal: Gut
Published: March 13, 2018

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 19, 2018

Pulmonary Thermal Ablation Enables Long Chemotherapy-Free Survival in Metastatic Colorectal Cancer Patients.

Pulmonary Thermal Ablation Enables Long Chemotherapy-Free Survival in Metastatic Colorectal Cancer Patients.

Journal: Cardiovascular and interventional radiology
Published: September 07, 2017

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 28, 2015

FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.

FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.

Journal: BMC research notes
Published: March 26, 2014

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 13, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026